Existing users Log In New users Sign up


COVID-19: Hematologic Parameters and their Implications

DISCOVERIES (ISSN 2359-7232), 2020, October-December issue

CITATION: 

Waleed RM, Sehar I, Iftikhar W, Khan HSHematologic parameters in coronavirus infection (COVID-19) and their clinical implications. Discoveries 2020, 8(4): e117. DOI: 10.15190/d.2020.14


Submitted: August 11, 2020; Revision: September 11, 2020; Accepted: September 17, 2020; Published: October 01, 2020; 

 GO BACK to 2020, October-December issue

 GO BACK to DISCOVERIES

Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications

Rao Muhammad Waleed (1,*), Inbisat Sehar (1), Waleed Iftikhar (1,2), Huma Saeed Khan (1)

(1) CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan

(2) California Institute of Behavioral Neurosciences & Psychology, Fairfield, CA 94534, USA


*Corresponding author: Rao Muhammad Waleed, CMH Lahore Medical College and Institute of Dentistry, Abdur Rehman Road, Lahore Cantonment, Pakistan; Email: raowaleed4@gmail.com

Abstract

Coronaviruses are a class of enveloped RNA viruses that cause infections of the respiratory tract, characterized by fever, tiredness, dry cough, diarrhea, loss of smell or taste, chest pain and shortness of breath. Many patients with mysterious pneumonia were distinguished in December 2019 in Wuhan. The pneumonia of obscure origin was found to be ascribed to a novel coronavirus and described as novel coronavirus pneumonia (NCP). The Chinese authorities initially reported the wave of mysterious pneumonia on December 31st, 2019 and it was declared as an outbreak of international concern on January 30th, 2020. A systematic search of relevant research was conducted, and a total of 58 primary research articles were identified, analyzed, and debated to better understand the hematologic profile in COVID-19 (Coronavirus disease) infection and its clinical implications. All the findings in this article manifest a true impression of the current interpretation of hematological findings of the SARS-COV-2 disease. Pathophysiology of COVID-19 disease can be better interpreted by taking into consideration the hematologic parameters. Clinical implications of the hematologic profile of COVID-19 patients including cytokine storm, coagulation profile, and thrombophilic complications are under-recognized. Therefore, this review focuses on the coagulation profile, cytokine storm, and its treatment options. The role of pre-existing thrombophilia in COVID-19 patients and how it could result in the poor prognosis of the disease is also debated. The recent data suggests that hypercoagulability could be the potential cause of fatalities due to COVID-19. Potential effects of tocilizumab, metronidazole, and ulinastatin in suppressing cytokine storm may help to treat SARS-COV-2 infection. This review also highlights the significance of thrombophilia testing in SARS-CoV-2 patients depending on the clinical features and especially in pregnant women.


Access full text of the manuscript here: 

References

1. Su S, Wong G, Shi W, Liu J, Lai A, Liu W. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology 2016;24(6):490-502.
2. Zhu N, Zhang D, Wang W, Yang B, Jingdong S. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine. 2020;2:727-35.
3. WHO. 2019 [cited 2020 August 8]. Available from: https://www.who.int/ith/diseases/sars/en/.
4. WHO. 2019 [cited 2020 August 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov).
5. Li Q, Guan X, Wu P, Wang X, Tong Y, Ren R. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. The New England Journal of Medicine. 2020;382(12).
6. Tang N, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostsis. 2020;18(4):844-7.
7. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020;7(1):1-10.
8. Huang C, Wang Y, Li X, Ren L, Zhao J. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
9. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020 Jun 1;77(6):683-690.
10. Madjid M, Naeini P, Solomon S, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System. JAMA Cardiology. 2020.
11. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nature Medicine. 2020;26(7):1017-32.
12. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. American Journal of Hematology. 2020;95(7):834-47.
13. Liu J, Li H, Luo M, Jiyang L, Lingzhen W, Lin X. Lymphopenia acted as an adverse factor for severity in patients with COVID-19: a single-centered, retrospecive study. Research Square. 2020(1).
14. Fan B, Chong V, Chan S, Lim G, Lim K, Tan G. Hematologic parameters in patients with COVID-19 infection. Journal of Hematology. 2020;95(6):131-4.
15. Huanhuan L, Liu F, Li J, Zhang T. Clinical and CT imaging features of COVID-19 pneumonia: Focus on pregnant women and children. Journal of Infection. 2020;80(5):7-13.
16. Frater J, Zini G, Onofrio G, Rogers H. COVID-19 and the clinical hematology laboratory. International Journal of Lab Hematology. 2020 Jun;42 Suppl 1:11-18.
17. Tan L, Wang Q, Zhang D. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther. 2020;33(5).
18. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & Infections. 2020;9(1):761-70.
19. Cascella M, Rajnik M, Cuomo A, Dulebohn S, Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. 2020.
20. Qing Y, Bili W, MD JM. Cytokine Storm in COVID-19 and Treatment. Journal of Infection. 2020.
21. Zhang W, Zhao Y, Zhang F. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology. 2020:214-5.
22. Zhang C, Zhao W, Jia-Wen L, Hong Z, Gui-Qiang W. The cytokine release syndrome (CRS) of sever COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International Journal of Antimicrobial Agents. 2020(2020):2015.
23. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. The American journal of emergency medicine. 2008;26(6):711-5.
24. Russell B, Moss C, George G, Santaolalla A, Cope A. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14(1022).
25. Liu B, Li M, Zhou z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome CRS)? Journal of autoimmunity. 2020 Jul;111:102452.
26. Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020 Mar 31;e33213321.
27. Wang L, Zhang Y, Zhang S. Cardiovascular Impairment in COVID-19: Learning from Current Options for Cardiovascular Anti-Inflammatory Therapy. Frontiers in Cardiovascular Medicine. 2020 Apr 30;7:78.
28. Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen. Archieves of Academic Emergency Medicine. 2020;8(1).
29. Shakir L, Javeed A, Ashraf M, Riaz A. Metronidazole and the immune system. Pharmazie. 2011;393(8).
30. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19. Journal of Translational Medicine. 2020 Apr 14;18(1):164.
31. Le R, Li L, Yuan W, Shord S, Nie L, Bahru H. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome. The Oncologist 2018; 23(8): 943-7.
32. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & Growth Factor Reviews. 2020;53:25-32.
33. Smetana K, Jr., Brábek J. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications. In Vivo. 2020;34(3 Suppl):1589-92.
34. Zhang X, Zhu Z, Jiao W, Liu W, Liu F, Zhu X. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulmonary Medicine. 2019;19(1):196.
35. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-13.
36. Wang H, Liu B, Tang Y, Chang P, Yao L, Huang B, et al. Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1370. 
37. Harzallah I, Debliquis A, Drenou B. Lupus anticoagulant is frequent in patients with Covid-19. Journal of Thrombosis haemostasis. 2020 Aug;18(8):2064-2065.
38. Zhai Z, Li C, Chen Y, X LZ, Z, Gerotziafas G, Liu P. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thrombosis and Haemostasis. 2020 Jun;120(6):937-948.
39. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. Jama. 2003;290(3):374-80.
40. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7): 934-943.
41. Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003 Jun 21; 326(7403): 1358-62.
42. Minet C, Potton L, Bonadona A. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Critical Care. 2015;19(1):287-9.
43. Shi S, Qin M, Shen B, Cai Y et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardio. 2020(e200950).
44. Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and Pregnancy Complications. Int J Mol Sci. 2015;16(12):28418-28.
45. Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S et al. COVID-19 and immunomodulation treatment for women with reproductive failures. Journal of Reproductive Immunology. 2020; 141: 103168.
46. Obradovic D. Thrombophilia and thrombosis. Medicinski pregled. 2005;58(7):368-74.
47. Dautaj A, Krasi G, Bushati V. Hereditary thrombophilia. Acta Biomed. 2019;90(10):44-6.
48. Kujovich J. Factor V Leiden Thrombophilia. Genet Med. 2011 Jan;13(1):1-16.
49. Cui S, Chen S, Li X, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostsis. 2020 Jun;18(6):1421-1424.
50. Siddique S, Risse J, Canaud G. Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy? Curr Rheumatol Rep. 2017;19(64).
51. Velasquez M, Rojas M, Cadavid A. Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association with Clinical Manifestations. Front Physiol. 2018 Dec 21;9:1840.
52. Canaud G, Bienaime F, Tabarin F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. New England Journal of Medicine. 2014;371(4):303-12.
53. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardio. 2020;17(5):259-60.
54. Shapiro S. The lupus anticoagulant/ antiphospholipid syndrome. Annu Rev Med. 1996:533-53.
55. Wang C, Greenbaum L. Nephrotic Syndrome. Pediatr Clin North Am. 2019;66(1):73-85.
56. Yang M, Pan X, Liang Z. Clinical Features of Nephrotic Syndrome with Cerebral Hemorrhage. Med Sci Monit. 2019;25:2179-85.
57. Sexton D, Clarkson M, Mazur M, Plant W, Eustace J. Serum D-dimer concentrations in nephrotic syndrome track with albuminuria, not estimated glomerular filtration rate. Am J Nephrol. 2012;36(6):554-60.
58. Cohoon KP, Mahé G, Spyropoulos AC. The underrecognized prothrombotic vascular disease of COVID-19. Res Pract Thromb Haemost. 2020;4(5):942-3.

News & Events Latest news from Discoveries

  • 2021, January| 2021 AWARDS!

    2021 DISCOVERIES AWARDS! Discoveries will offer a $1000 award and at least five $400 awards in Jan 2022, for the most cited (2021 ISI Citations) and visible (Altmetric Score) articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.